Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis

Table 2 Baseline costs, risks, and utility values included in model

Parameter	VALUE	LOW	HIGH	Distributions	Reference
Costs ($)^a					[20]
CAPOX	244.97	195.98	293.97	Gamma
CAPOX + Trastuzumab	713.95	571.16	856.74	Gamma
FOLFOX	276.57	221.26	331.88	Gamma
FOLFOX + Trastuzumab	882.28	705.83	1058.74	Gamma
Costs on main AEs^b($)					[20]
Hand-foot syndrome	8.05	6.44	9.66	Normal
Gastrointestinal disorders	1.60	1.28	1.92	Normal
thrombocytopenia	64.20	51.36	77.03	Normal
Anemia	6.93	5.55	8.32	Normal
Neutropenia	9.17	7.34	11.00	Normal
Costs of states ($)					[20]
PFS^c	95.62	76.49	114.74	Gamma
PP^d	117.62	94.10	141.15	Gamma
Probability of main AEs (%)
FOLFOX					[15, 17]
Hand-foot syndrome	0.55	0.44	0.66	Beta
Gastrointestinal disorders	8.66	6.928	10.392	Beta
thrombocytopenia	1.43	1.144	1.716	Beta
Anemia	3.25	2.6	3.9	Beta
Neutropenia	10.03	8.024	12.036	Beta
CAPOX					[16,17,18]
Hand-foot syndrome	2.39	1.912	2.868	Beta
Gastrointestinal disorders	2.16	1.728	2.592	Beta
thrombocytopenia	0.91	0.728	1.092	Beta
Anemia	2.03	1.624	2.436	Beta
Neutropenia	4.78	3.824	5.736	Beta
Utility					[21]
PFS	0.81	0.648	0.972	Beta
PP	0.6	0.480	0.720	Beta
Disutility					[21]
AE	0.15	0.120	0.180	Beta
BD^e	0.079	0.063	0.095	Beta

(a) Year-2022 US $; local charges, (b) AE: Adverse Events, (c) PFS: Progression Free Survival, (d) PP: Post Progress, (e) BD: Before Death

ISSN: 2191-1991